Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)
Others
Ratios

Benitec Biopharma (BNTC) Research & Development (2019 - 2025)

Benitec Biopharma's Research & Development history spans 7 years, with the latest figure at $6.0 million for Q1 2025.

  • For Q1 2025, Research & Development rose 133.05% year-over-year to $6.0 million; the TTM value through Mar 2025 reached $18.5 million, up 20.8%, while the annual FY2024 figure was $15.6 million, 22.19% up from the prior year.
  • Research & Development for Q1 2025 was $6.0 million at Benitec Biopharma, up from $5.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $6.0 million in Q1 2025 and bottomed at $2.2 million in Q1 2022.
  • The 5-year median for Research & Development is $3.2 million (2022), against an average of $3.5 million.
  • The largest annual shift saw Research & Development surged 259.17% in 2021 before it decreased 21.28% in 2022.
  • A 5-year view of Research & Development shows it stood at $3.1 million in 2021, then rose by 19.55% to $3.8 million in 2022, then soared by 35.66% to $5.1 million in 2023, then grew by 5.55% to $5.4 million in 2024, then increased by 11.05% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Research & Development are $6.0 million (Q1 2025), $5.4 million (Q4 2024), and $3.6 million (Q3 2024).